Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial

or

Watchlist | Portfolio | Dashboard

quotes
- Price Overview
- Performance Report
charts
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Neurobo Pharmaceuticals Inc (NRBO)

Neurobo Pharmaceuticals Inc (NRBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference PR Newswire - Tue Oct 17, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH PR Newswire - Fri Sep 15, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Wed Aug 9, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH PR Newswire - Thu Aug 3, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01 PR Newswire - Wed Aug 2, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models PR Newswire - Tue Jun 27, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions PR Newswire - Tue Jun 13, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors PR Newswire - Fri May 12, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH PR Newswire - Tue May 2, 2023

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Use your up/down arrows to move through the symbols.

Free Barchart Webinar